AIM Vaccine Future Growth

Future criteria checks 3/6

AIM Vaccine is forecast to grow revenue at 48.4% per annum.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth38.9%
Revenue growth rate48.4%
Future return on equity22.2%
Analyst coverage

Low

Last updated13 Feb 2025

Recent future growth updates

No updates

Recent updates

Here's Why AIM Vaccine (HKG:6660) Can Afford Some Debt

Nov 15
Here's Why AIM Vaccine (HKG:6660) Can Afford Some Debt

Why Investors Shouldn't Be Surprised By AIM Vaccine Co., Ltd.'s (HKG:6660) 27% Share Price Plunge

Aug 24
Why Investors Shouldn't Be Surprised By AIM Vaccine Co., Ltd.'s (HKG:6660) 27% Share Price Plunge

It's A Story Of Risk Vs Reward With AIM Vaccine Co., Ltd. (HKG:6660)

May 29
It's A Story Of Risk Vs Reward With AIM Vaccine Co., Ltd. (HKG:6660)

Investor Optimism Abounds AIM Vaccine Co., Ltd. (HKG:6660) But Growth Is Lacking

Jun 09
Investor Optimism Abounds AIM Vaccine Co., Ltd. (HKG:6660) But Growth Is Lacking

Earnings and Revenue Growth Forecasts

SEHK:6660 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20275,514N/AN/A1,2391
12/31/20263,807N/AN/A9001
12/31/20251,462N/AN/A7271
12/31/20241,247N/AN/A1771
6/30/20241,184-1,190-276-14N/A
3/31/20241,186-1,245-340-90N/A
12/31/20231,187-1,301-405-165N/A
9/30/20231,200-913-593-224N/A
6/30/20231,213-525-781-283N/A
3/31/20231,239-422-874-197N/A
12/31/20221,264-320-967-110N/A
12/31/20211,570-693-1,03293N/A
12/31/20201,638379-416250N/A
12/31/201995211712327N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 6660's forecast earnings growth is above the savings rate (2.4%).

Earnings vs Market: Insufficient data to determine if 6660's earnings are forecast to grow faster than the Hong Kong market

High Growth Earnings: Insufficient data to determine if 6660's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 6660's revenue (48.4% per year) is forecast to grow faster than the Hong Kong market (8% per year).

High Growth Revenue: 6660's revenue (48.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 6660's Return on Equity is forecast to be high in 3 years time (22.2%)


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/25 14:15
End of Day Share Price 2025/02/25 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

AIM Vaccine Co., Ltd. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullFosun International Securities Limited
Tony RenMacquarie Research